Abstract
To examine mediators of mifepristone treatment on improvements in health-related quality of life (HRQOL) among women with symptomatic fibroids. The study sample included women with symptomatic uterine fibroids who were treated with 5mg or 2.5mg of mifepristone or placebo. Assessments of uterine size (ultrasound), pain (McGill pain questionnaire), bleeding (diary), anemia (gm/dL), and HRQOL measured using the uterine fibroid symptom quality of life scale were done at baseline, 3 months, and 6 months. The improvements in HRQOL that could be explained by changes in these clinical factors were assessed. The final sample included 62 women. Treatment with mifepristone was associated with significant improvement in HRQOL, which was explained in part by reduction in pain (28%, P<0.001) and bleeding (18%, P<0.001). Reduction in uterine volume was of marginal significance (P=0.05) and was associated with a decrease in HRQOL (7%). Much of the impact of treatment on HRQOL (61%) remained unexplained in this model. Improvements in HRQOL after treatment with mifepristone are partly explained by improvements in pain and bleeding, but not uterine size. However, most of the improvement in HRQOL is not explained by improvements in these clinical ...Continue Reading
References
Aug 1, 1990·British Journal of Obstetrics and Gynaecology·J M HighamR W Shaw
Jun 1, 1995·Obstetrics and Gynecology·C A JanssenA P Heintz
Jan 1, 1996·Magnetic Resonance Imaging·F J BroekmansJ Schoemaker
Dec 16, 1997·Obstetrics and Gynecology·L M MarshallD J Hunter
Jun 3, 1999·The Surgical Clinics of North America·J Katz, R Melzack
Jan 30, 2002·Obstetrics and Gynecology·James B SpiesSheila M Gonzalves
Feb 11, 2003·Obstetrics and Gynecology·Steven H EisingerDavid S Guzick
Dec 2, 2005·Obstetrics and Gynecology·James B SpiesUNKNOWN FIBROID Registry Investigators
Oct 13, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Pao-Ling TorngTa-Chen Su
Nov 8, 2006·Brain, Behavior, and Immunity·Robert Dantzer, Keith W Kelley
Dec 2, 2006·Obstetrics and Gynecology·Kevin FiscellaDavid S Guzick
Oct 14, 2008·Journal of Occupational and Environmental Medicine·Debra LernerDavid Chelmow
Nov 4, 2008·Obstetrics and Gynecology·Josep Lluis Carbonell EsteveAleta Valle Hernández
Mar 14, 2009·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Madhu BagariaKiran Mishra
Jul 10, 2009·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Steve H EisingerKevin Fiscella
Citations
May 16, 2012·Journal of Assisted Reproduction and Genetics·Gary LevyWilliam H Catherino
Jul 27, 2011·Human Reproduction Update·Pasquapina CiarmelaMario Castellucci
Jul 1, 2014·Maturitas·Faustino R Pérez-LópezMargaret Rees
May 3, 2014·Expert Opinion on Pharmacotherapy·Giuseppe BenagianoIvo Brosens
Oct 8, 2013·Fertility and Sterility·Qi ShenXueqiong Zhu
Nov 11, 2011·Journal de gynécologie, obstétrique et biologie de la reproduction·M KoskasJ Derrien
Sep 29, 2011·Fertility and Sterility·Philippe BouchardBart C J M Fauser
Jun 16, 2011·Molecular and Cellular Endocrinology·J Julie Kim, Elizabeth C Sefton
May 17, 2012·Journal of Midwifery & Women's Health·Kate E RiceJeremy L Neal
Aug 29, 2013·ISRN Obstetrics and Gynecology·Josep Lluis CarbonellGiuseppe Tomasi
Aug 31, 2014·Fertility and Sterility·Nathalie Chabbert-BuffetPhilippe Bouchard
Sep 22, 2018·The Journal of Clinical Endocrinology and Metabolism·Sinnie Sin Man NgJames H Segars
Mar 23, 2018·Obstetrics & Gynecology Science·Geum Seon SohnUNKNOWN Working Group of Society of Uterine Leiomyoma
Apr 30, 2021·Reproductive Sciences·Bhuchitra SinghJames H Segars